Leslie Hudson, PhD, served as the CEO of Sarepta Therapeutics, Inc. from July 2008 until April 2010. With a PhD in Molecular Biology, he helped steer the company through key developments in biotechnology, particularly in RNA therapeutics aimed at genetic...
Leslie Hudson, PhD, served as the CEO of Sarepta Therapeutics, Inc. from July 2008 until April 2010. With a PhD in Molecular Biology, he helped steer the company through key developments in biotechnology, particularly in RNA therapeutics aimed at genetic diseases. Hudson left a mark by overseeing substantial projects that involved innovative approaches for treating conditions like Duchenne muscular dystrophy. His tenure was cut short when he resigned, which the company treated as an involuntary termination. During his time, he also faced significant challenges, being ineligible for performance bonuses in his final year due to his departure. In his earlier years, Hudson held several senior roles, including CEO of DOV Pharmaceutical and Vice Provost at the University of Pennsylvania, expanding his expertise in leadership within the biotech sector. Known for his strategic insights, Hudson's time at Sarepta shaped the company's vision and direction during a pivotal period.